Zymeworks Chief Finance, Medical, Scientific Officers Leaving in Executive Reorg

Dow Jones01-12

By Colin Kellaher

Zymeworks unveiled a C-suite realignment that includes the departure of the biotechnology company's top finance and science officers.

Zymeworks on Monday said the moves are aimed at aligning key leadership roles with the corporate strategy the company announced in November.

Zymeworks said Leone Patterson, who joined the company as executive vice president and chief financial and business officer in September 2024, will leave the company during the first quarter.

Zymeworks said its chairman and chief executive, Kenneth Galbraith, has stepped in as interim finance chief while the company conducts a search for a successor.

Mark Hollywood, who joined Zymeworks in 2019 and had been executive vice president and head of technical and manufacturing operations, will now serve as executive vice president and chief operating officer, with expanded responsibilities, the company said.

Zymeworks said Jeff Smith, who has been chief medical officer since January 2024, will retire at the end of the month.

Sabeen Mekan, currently senior vice president of clinical development, will succeed Smith as chief medical officer, the company said.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 12, 2026 06:34 ET (11:34 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602511370?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602511370","market":"hk","top_or_hot":-1,"title":"Zymeworks Chief Finance, Medical, Scientific Officers Leaving in Executive Reorg","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Zymeworks unveiled a C-suite realignment that includes the departure of the biotechnology company's top finance and science officers. \n</p>\n<p>\n  Zymeworks on Monday said the moves are aimed at aligning key leadership roles with the corporate strategy the company announced in November. \n</p>\n<p>\n  Zymeworks said Leone Patterson, who joined the company as executive vice president and chief financial and business officer in September 2024, will leave the company during the first quarter. \n</p>\n<p>\n  Zymeworks said its chairman and chief executive, Kenneth Galbraith, has stepped in as interim finance chief while the company conducts a search for a successor. \n</p>\n<p>\n  Mark Hollywood, who joined Zymeworks in 2019 and had been executive vice president and head of technical and manufacturing operations, will now serve as executive vice president and chief operating officer, with expanded responsibilities, the company said. \n</p>\n<p>\n  Zymeworks said Jeff Smith, who has been chief medical officer since January 2024, will retire at the end of the month. \n</p>\n<p>\n  Sabeen Mekan, currently senior vice president of clinical development, will succeed Smith as chief medical officer, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 06:34 ET (11:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zymeworks Chief Finance, Medical, Scientific Officers Leaving in Executive Reorg</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZymeworks Chief Finance, Medical, Scientific Officers Leaving in Executive Reorg\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-12 19:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Zymeworks unveiled a C-suite realignment that includes the departure of the biotechnology company's top finance and science officers. \n</p>\n<p>\n  Zymeworks on Monday said the moves are aimed at aligning key leadership roles with the corporate strategy the company announced in November. \n</p>\n<p>\n  Zymeworks said Leone Patterson, who joined the company as executive vice president and chief financial and business officer in September 2024, will leave the company during the first quarter. \n</p>\n<p>\n  Zymeworks said its chairman and chief executive, Kenneth Galbraith, has stepped in as interim finance chief while the company conducts a search for a successor. \n</p>\n<p>\n  Mark Hollywood, who joined Zymeworks in 2019 and had been executive vice president and head of technical and manufacturing operations, will now serve as executive vice president and chief operating officer, with expanded responsibilities, the company said. \n</p>\n<p>\n  Zymeworks said Jeff Smith, who has been chief medical officer since January 2024, will retire at the end of the month. \n</p>\n<p>\n  Sabeen Mekan, currently senior vice president of clinical development, will succeed Smith as chief medical officer, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 06:34 ET (11:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602511370","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602511370","pubTimestamp":1768217640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Zymeworks unveiled a C-suite realignment that includes the departure of the biotechnology company's top finance and science officers.Zymeworks on Monday said the moves are aimed at aligning key leadership roles with the corporate strategy the company announced in November.Zymeworks said Leone Patterson, who joined the company as executive vice president and chief financial and business officer in September 2024, will leave the company during the first quarter.Zymeworks said its chairman and chief executive, Kenneth Galbraith, has stepped in as interim finance chief while the company conducts a search for a successor.Mark Hollywood, who joined Zymeworks in 2019 and had been executive vice president and head of technical and manufacturing operations, will now serve as executive vice president and chief operating officer, with expanded responsibilities, the company said.Zymeworks said Jeff Smith, who has been chief medical officer since January 2024, will retire at the end of the month.Sa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ZYME":"ZYMEWORKS INC (US)"},"translate_title":"Zymeworks首席财务、医疗、科学官因高管重组而离职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZYME":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Zymeworks unveiled a C-suite realignment that includes the departure of the biotechnology company's top finance and science officers. \n\n\n  Zymeworks on Monday said the moves are aimed at aligning key leadership roles with the corporate strategy the company announced in November. \n\n\n  Zymeworks said Leone Patterson, who joined the company as executive vice president and chief financial and business officer in September 2024, will leave the company during the first quarter. \n\n\n  Zymeworks said its chairman and chief executive, Kenneth Galbraith, has stepped in as interim finance chief while the company conducts a search for a successor. \n\n\n  Mark Hollywood, who joined Zymeworks in 2019 and had been executive vice president and head of technical and manufacturing operations, will now serve as executive vice president and chief operating officer, with expanded responsibilities, the company said. \n\n\n  Zymeworks said Jeff Smith, who has been chief medical officer since January 2024, will retire at the end of the month. \n\n\n  Sabeen Mekan, currently senior vice president of clinical development, will succeed Smith as chief medical officer, the company said. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 06:34 ET (11:34 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602511370","isCrawlerRequest":true}